Skip to main content

Table 1 Descriptions of human lentivirus (LV) and murine leukemia virus (MLV) vector integration site (VIS) data sets.

From: Methodology and software to detect viral integration site hot-spots

Data set Name Study # Type # VIS Time points Cell Type
H-LV-XALD X-Linked ALD [8] 2 LV 2401 6-24 m CD:34,15,3,14,16,19,56, LM
H-LV-Patient1 X-Linked ALD [8] 1 LV 1627 6-24 m CD:34,15,3,14,16,19,56, LM
H-LV-Patient2 X-Linked ALD [8] 1 LV 774 6-20 m CD:34,15,3,14,16,19
H-LV-acute X-Linked ALD [8] pre LV 922 -- CD34
H-MLV-XCGD CGD [9] 2 MLV 384 1-45 m CD:3,14,15,19; PB, BM, G
H-MLV-XSCID SCIDX1 [6, 7] 14 MLV 864 4-41 m CD:3,13,14,19; PBL, PBMC
-- SCIDX1 [6] 5 MLV 303 9-30 m CD:3, 13
-- SCIDX1 [7] 9 MLV 561 4-41 m CD:3,14,19; PBL, PBMC
H-MLV-acute GFP [20] pre MLV 1398 1-12 days PT CD34
  1. The seven data sets analyzed here originated from five LV and MLV studies. Column one indicates the data set name given in this paper, and the 'Study' column indicates the parent study where X-linked ALD (adrenoleukodystrophy), CGD (chronic granulomatous disease) and SCIDX1 (X-linked severe combined immunodeficiency) refer to human clinical trials, and GFP (green fluorescent protein) indicates a control vector study. The H-MLV-XSCID data set was derived from two different studies [6, 7] as indicated. The '#' column indicates the number of subjects analyzed; 'Type' refers to vector type, LV or MLV; '# VIS' indicates the number of unique vector integration sites; 'Time points' indicates the number of time points from which samples were obtained; and 'Cell Type' indicates the cells from which VIS were derived. LAM sequencing was used exclusively in all studies except the GFP study which used an LM/LAM combination.